Year: 2026 | Month: January | Volume: 16 | Issue: 1 | Pages: 16-25
DOI: https://doi.org/10.52403/ijhsr.20260103
A Study of Expression of Mammoglobin and Gross Cystic Disease Fluid Protein-15 In Breast Cancer
Neha Suman1, Manjula Jain2, Anita Nangia3, Shaji Thomas4
1Assistant Professor, Department of Pathology, Lady Hardinge Medical College, New Delhi,
2Ex-Director Professor & HOD, Department of Pathology, Lady Hardinge Medical College, New Delhi
3Ex-Director Professor, Department of Pathology, Lady Hardinge Medical College, New Delhi
4Ex-Director Professor & HOD, Department of Surgery, Lady Hardinge Medical College, New Delhi
Corresponding Author: Dr Neha Suman
ABSTRACT
Background: Breast cancer is the most common cancer in women worldwide. There is a lack of tissue markers with sufficient sensitivity and/or specificity for detection, and disease evolution in breast cancer. Clinically, ER, PR and HER-2 are the most useful immunomarkers for prognosis and therapy but these are not breast specific. Mammoglobin (MGB) and Gross Cystic Disease Fluid Protein (GCDFP-15) have been suggested as highly specific for mammary differentiation. As there are few studies which have studied the relation of expression of mammoglobin and GCDFP-15 to molecular classification of breast cancer hence there is the need to study these markers.
Aims: To determine expression of mammoglobin and GCDFP-15 in breast carcinoma on tru-cut biopsy specimens and the association of expression of mammoglobin and GCDFP with molecular classification of breast carcinoma using surrogate panel of immunohistochemical markers.
Settings and design: Hospital based descriptive observational cross-sectional study.
Material and methods: Immunohistochemical analysis was conducted on 35 cases of breast carcinoma proven on biopsy/trucut biopsy. The immunohistochemical expression of mammoglobin and GCDFP-15 were analysed and further staining scores were done. Correlation with clinicopathologic parameters and molecular classification of breast carcinoma was done.
Results: 11/35 (31.4%) cases were positive for mammoglobin expression and 9/35 (26.5%) cases were positive for GCDFP. There was overexpression of mammoglobin and GCDFP-15 in Luminal A and Her2 classic cases. Higher mammoglobin score was observed in Luminal A tumors. Most triple negative tumors were negative for mammoglobin and GCDFP-15.
Conclusion: There is overexpression of mammoglobin and GCDFP-15 in breast carcinoma and these markers can serve as a novel and clinically useful immunomarker for breast carcinoma.
Key words: Breast carcinoma, GCDFP-15, Mammoglobin